USPTO trademark

Ascentage Pharma (Suzhou) Co., Ltd design mark 8184498

RegisteredUSPTOFigurative markClass 5

"Design mark 8184498" is a figurative mark owned by Ascentage Pharma (Suzhou) Co., Ltd., filed at the USPTO on July 20, 2025. It is registered and covers class 5 (Pharmaceuticals).

View Ascentage Pharma (Suzhou) Co., Ltd. portfolio Get this data via the API

Data current as of April 3, 2026Official USPTO record

As filed with the USPTO

Status: Registered; Since March 24, 2026
Filed: July 20, 2025
Registered: March 24, 2026
Priority date: January 20, 2025; Claimed from China
Application no.: 99293055
Registration no.: 8184498
Office: USPTO; United States Patent and Trademark Office
Mark type: Figurative mark; 1 class

Ownership

Who owns Ascentage Pharma (Suzhou) Co., Ltd design mark 8184498

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Ascentage Pharma (Suzhou) Co., Ltd.

Jiangsu, China

20 trademarks in the portfolioView company

Representative

Kathryn E. Smith

Wood Herron & Evans LLP

Goods and services

What the mark covers

The products and services Ascentage Pharma (Suzhou) Co., Ltd design mark 8184498 is filed for, grouped by Nice class.

05Class 5 · Pharmaceuticals
Medicines for human purposes for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Chemical preparations for medical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs sold in bulk, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biochemical medicines for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compounds, next-generation kinase inhibitors and senolytic drugs; biological preparations for medical purposes, namely, biological preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical preparations for pharmaceutical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; radioactive substances for medical purposes; gases for medical purposes, namely, nitric oxide for medical purposes; chemical conductors for electrocardiograph electrodes; semen for artificial insemination; disinfectants; solutions for contact lenses; cultures of microorganisms for medical or veterinary use; medicated sweets; dietetic preparations adapted for medical purposes; depuratives for the body; diagnostic preparations for veterinary purposes; pesticides; sanitary napkins; cotton for medical purposes; dental abrasives; diapers for pets

History

What has happened so far

Steps recorded by the USPTO, newest first.

March 24, 2026Notice of registration confirmation emailed
March 24, 2026Registered-principal register
February 3, 2026Official gazette publication confirmation e-mailed
February 3, 2026Published for opposition
January 28, 2026Notification of notice of publication e-mailed
January 12, 2026Approved for pub - principal register
December 5, 2025Teas/email correspondence entered
December 5, 2025Correspondence received in law office
December 5, 2025Teas response to office action received
September 10, 2025Notification of non-final action e-mailed

7 earlier steps on the official record.

FAQ

About Ascentage Pharma (Suzhou) Co., Ltd design mark 8184498

Who owns the trademark "Design mark 8184498"?

The USPTO trademark "Design mark 8184498" (application 99293055) is owned by Ascentage Pharma (Suzhou) Co., Ltd.

What is the status of "Design mark 8184498"?

Its status at the USPTO is: registered.

When was "Design mark 8184498" registered?

It was registered on March 24, 2026.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull Ascentage Pharma (Suzhou) Co., Ltd design mark 8184498 and marks like it into your own product with one request.

GET/v1/trademarks/{id}
The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/events
Every step in the office history
GET/v1/proceedings?trademark_id={id}
Oppositions and cancellations against the mark

Get API key View docs

GET /v1/trademarks/{id}

ID=tm_019d2afb-f335-7678-969f-08e98f282207
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"

Response

{
  "id": "tm_019d2afb-f335-7678-969f-08e98f282207",
  "object": "trademark",
  "mark_text": "[Design Mark]",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "US",
  "application_number": "99293055",
  "filing_date": "2025-07-20",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "ASCENTAGE PHARMA (SUZHOU) CO., LTD.",
      "entity_id": "ent_019eb7d1-fa6d-74ef-aad1-d36b9d2a9480"
    }
  ]
}